KPV | 10mg

KPV | 10mg

KPV is supplied strictly as a laboratory research material for analytical and scientific use only. Available to qualified researchers, laboratories, and institutions in Perth and across Western Australia, with Australian-based fulfilment.

Intended for in‑vitro research, assay development, method validation, and controlled scientific investigation by appropriately qualified professionals.

Product details

• Product: KPV
• Molecular Formula: C₁₆H₃₀N₄O₄
• Strength / size: KPV 10 Mg
• Category: Research compound / research peptide
• Form: Lyophilised powder
• Use: Laboratory research only
• Supply: Perth & Western Australia (AU shipping)

SEQUENCE: Lys-Pro-Val

OTHER KNOWN TITLES: MSH(11-13), ACTH(11-13), alpha-MSH(11-13)

KPV is the C-terminal peptide stretch of alpha-melanocyte-stimulating hormone (alpha-MSH). The peptide consists of the last three amino acids of the alpha-MSH hormone. It has been explored for its potential anti-inflammatory properties at the cellular level. Comprising the amino acids L-Lys-L-Pro-L-Val, KPV represents the minimal sequence that may mitigate inflammation in experimental models. However, the precise mechanisms of its action still need to be further studied in order to be more fully understood.

This peptide’s various mechanisms may potentially differentiate from that of alpha-MSH, which researchers believe interacts with the melanocortin-1 receptors by theoretically activating the cAMP pathway. Instead, studies suggest a rapid and acute increase in intracellular calcium when KPV is introduced alongside N6-(L-2-phenyl isopropyl) adenosine (PIA), an adenosine agonist that inhibits the cAMP pathway.

Further data-gathering investigations using cells transfected with melanocortin-1 receptors have indicated that KPV may, in theory, elevate intracellular calcium levels. This may imply an additional type of interaction with this receptor. This calcium signaling is thought to contribute to the inhibition of the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a transcription factor involved in inflammatory responses. By potentially inhibiting NF-κB activation, KPV might modulate inflammatory processes within cells.